Monsanto Co. v. Syngenta Seeds, Inc.

503 F.3d 1352, 84 U.S.P.Q. 2d (BNA) 1705, 2007 U.S. App. LEXIS 23255, 2007 WL 2874217

• Court: Court of Appeals for the Federal Circuit
• Decided: October 4, 2007
• Docket: 2006-1472
• Status: Published

Opinion

RADER, Circuit Judge.

On summary judgment, the United States District Court for the District of Delaware determined that Defendants-Ap-pellees Syngenta Seeds, Inc.; Syngenta Biotechnology, Inc.; Garst Seeds Company; Golden Harvest Seeds, Inc.; Garwood Seed Co.; Golden Seed Co., LLC; Sokmer Bros. Seed Company; Thorp Seed Co. and JC Robinson Seeds, Inc., (collectively “Syngenta”), did not infringe the asserted claims of U.S. Patents Nos. 5,538,880 and 6,013,863 (“the Lundquist patents”). Monsanto Co. v. Syngenta Seeds, Inc., 431 F.Supp.2d 482, 487 (D.Del.2006). The trial court also held claims 1, 5 and 6 of U.S. Patent No. 4,940,835 (“the '835 patent”) invalid under 35 U.S.C. § 112 for lack of enablement. Id. at 490. Finding no error, this court affirms.

I

This case involves three patents: U.S. Patents Nos. 5,538,880 (“the '880 patent”), 6,013,863 (“the '863 patent”), and the '835 patent. The three patents-in-suit involve technologies for producing transgenic corn (“GA21”) that is resistant to glyphosate, a nonselective herbicide. The '835 patent, owned by Monsanto Company, claims a chimeric plant gene (DNA) that confers the glyphosate resistance to plants. The Lundquist patents, owned by Dekalb Genetics Corporation (“Dekalb”), Monsanto’s wholly owned subsidiary, include methods of producing herbicide resistant transgenic corn (Zea mays) plants and seeds. The '880 patent differs slightly from the '863 patent. Specifically, the '880 patent claims the process of producing transgenic herbicide resistant corn and also insect resistant corn; the '863 patent claims the process of producing glyphosate resistant transgenic corn having a screenable marker gene.

On May 12, 2004, Monsanto Company and Monsanto Technology LLC filed a suit against Syngenta Seeds and Syngenta Biotechnology, Inc. in the District Court of Delaware alleging infringement of the '835 patent. A few months later, on July 27, 2004, Dekalb Genetics Corporation sued Syngenta Seeds and Syngenta Biotechnology, Inc. 1 in the Northern District of Illinois alleging infringement of the Lundquist patents. 2 On May 19, 2005, the District Court in Illinois granted Syngen-ta’s motion to transfer the suit to Delaware.

Dekalb and Monsanto (collectively “Monsanto”) allege that Syngenta used GA21 seed acquired from Monsanto’s licensees to produce further progeny containing the GA21 trait, thereby infringing the claims of the '835 patent, claims 4-9 of the '880 patent and claims 5-6 of the '863 patent. Noting Dekalb itself performed the three steps of the independent claims of the '880 and '863 patents, Syngenta argues it did not infringe the Lundquist patents because it did not carry out all the steps of the asserted claimed processes during the term of the patent. Syngenta also counterclaims that the '835 patent application did not enable the asserted claims of the '835 patent.

Syngenta makes and sells genetically engineered crops. Syngenta obtained GAB seeds when it acquired two seed companies, Garst Seed Company (“Garst”) and Golden Harvest Seeds, Inc. (“Golden Harvest”), licensed to sell GA21 seed to farmers. Monsanto does not dispute that De-kalb made the original transgenic GA21 corn using a glyphosate resistant gene obtained from Bayer AG. Nor does Monsanto dispute that in making the original transgenic GA21 corn, Dekalb performed the steps recited in claim 1 of both Lundquist patents. Indeed, Monsanto does not dispute that the original transgenic GA21 corn was produced in 1992-93, before issuance of either of the Lundquist patents (the '880 patent issued July 23, 1996; the '863 patent January 11, 2000).

Claims 4-9 of the '880 patent read:

4. A process comprising obtaining progeny from a fertile transgenic plant obtained by the process of claim 1 which comprise said DNA.

5. The process of claim 4 wherein said progeny are obtained by crossing said fertile transgenic plant with an inbred line.

6. The process of claim 4 comprising obtaining seed from said progeny plants comprising said DNA from said seed.

7. The process of claim 5 wherein the progeny obtained are crossed back to the inbred line, to obtain further progeny which comprise said DNA.

8. The process of claim 6 wherein seed are obtained from said further progeny plants and plants comprising said DNA are recovered from said seed.

9. The process of claim 7 wherein said further progeny are crossed back to the inbred line to obtain progeny which comprise said DNA.

(emphases added). Claims 5-6 of the '863 patent read:

5. The process of claim 1 further comprising obtaining transgenic glyphosate resistant progeny plants of subsequent generations from said fertile transgenic plant.

6. The process of claim 5 further comprising obtaining seed from one of said progeny plants.

After claim construction, the Delaware District Court granted Syngenta’s motions for summary judgment on May 10, 2006, finding the Lundquist patents not infringed because the patent holder (Monsanto through Dekalb) performed the initial steps of the claimed processes. The trial court also found claims 1, 5 and 6 of the '835 patent invalid for lack of enablement. Monsanto, 431 F.Supp.2d at 490. The district court specifically noted that Syngenta lawfully obtained the GA21 seeds from Monsanto’s licensees, such as Garst and Golden Harvest. Upon obtaining the seeds, Syngenta also acquired the right to further produce GA21 progenies containing the glyphosate resistance trait. Id. at 487. Also, Monsanto itself (through its subsidiary Dekalb) made the original GA21 R0 plant, at a time before issuance of the Lundquist patents. Id.

On June 6, 2006, the district court entered a final judgment in favor of Syngen-ta and against Monsanto on both Monsanto’s claim of infringement and Syngenta’s counterclaim of invalidity under 35 U.S.C. § 112.

II

This court reviews a district court’s grant of summary judgment without deference. Johns Hopkins Univ. v. CellPro, Inc., 152 F.3d 1342, 1353 (Fed.Cir.1998); Conroy v. Reebok Int’l, Ltd., 14 F.3d 1570, 1574 (Fed.Cir.1994). Thus, this court decides for itself “if the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law.” Fed. R.Civ.P. 56(c); Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). In applying this standard, this court draws all reasonable inferences in the nonmovant’s favor. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986).

“An infringement analysis entails two steps. The first step is determining the meaning and scope of the patent claims asserted to be infringed. The second step is comparing the properly construed claims to the device accused of infringing.” Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed.Cir.1995) (en banc), aff'd, 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996) (citations omitted). The claim construction part of this test receives review as a question of law, see Cybor Corp. v. FAS Techs. Inc., 138 F.3d 1448, 1451 (Fed.Cir.1998) (en banc), while infringement, whether literal or under the doctrine of equivalents, is a question of fact. Optical Disc Corp. v. Del Mar Avionics, 208 F.3d 1324, 1333-34 (Fed.Cir.2000); Bai v. L & L Wings, Inc., 160 F.3d 1350, 1353 (Fed.Cir.1998).

This court reviews determinations of enablement under 35 U.S.C. § 112, first paragraph, without deference. Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1268 (Fed.Cir.1986). Factual issues underlying enablement are reviewed for clear error. Gould v. Quigg, 822 F.2d 1074, 1077 (Fed.Cir.1987); Atlas Powder Co. v. E.I. du Pont De Nemours & Co., 750 F.2d 1569, 1573 (Fed.Cir.1984) (appellant must establish that the district court’s legal conclusions were erroneous, or that the underlying findings were clearly erroneous); see also Anderson v. Bessemer City, 470 U.S. 564, 573, 105 S.Ct. 1504, 84 L.Ed.2d 518 (1985).

Because Dekalb performed all the steps of claim 1 of both Lundquist patents, Monsanto necessarily asserted claims other than claim 1 (4-9 of the '880 patent and 5-6 of the '863 patent). Monsanto proffers two theories of infringement. First, Monsanto argues claim 4 of the '880 patent is an independent claim, thus not requiring an alleged infringer to perform the steps of claim 1. Second, Monsanto argues that, even if claim 4 is dependent on claim 1, Syngenta infringes because .Syngenta’s performance of the last step of the process of claim 4 resulted in performance of all of the claimed steps of claim 4, albeit with the first three steps performed by Monsanto.

Syngenta responds that claim 4 of the '880 patent depends on claim 1 and therefore includes all the steps of claim 1. Thus, claim 4 can only be infringed by the unauthorized performance of all the steps of claims 1 and 4. Consequently, because Monsanto (the patent holder) admittedly performed the steps of claim 1, Syngenta cannot infringe as a matter of law.

A. Claim Construction

The district court construed claims 4-9 of the '880 patent and claims 5-6 of the '863 patent as dependent from claim 1 of their respective patents. Claim 1 of the '880 patent recites a three-step process for generating an original RO fertile transgenic plant containing DNA that provides herbicide resistance. The district court construed claim 4 as further adding a fourth step of obtaining progeny from a fertile transgenic plant produced by the process of claim 1. Monsanto, 431 F.Supp.2d at 485.

Claims 5-9 of the '880 patent and claims 5-6 of the '863 patent fit the traditional dependent format. Claim 4 of the '880 patent features a format closely following the traditional dependent format. Although suggesting the correctness of the trial court’s construction, this format, however, does not answer the entire question. Monsanto urges that claim 4 of the '880 patent is not “simply” a dependent claim because it entails significantly more than the process of claim 1. According to Monsanto, claim 4 is by itself a single-step process (process of obtaining progeny). Under Monsanto’s construction, the dependent language refers instead to the novel starting material (a fertile transgenic plant previously obtained using the claim 1 process) of the new process in claim 4. To bolster its point, Monsanto draws attention to the form of claim 4, which differs a bit from the customary dependent claim format (i.e., “the process of claim 1 further comprising ...”).

To establish whether a claim is dependent upon another, this court examines if the new claim both refers to an earlier claim and further limits that referent. 35 U.S.C § 112, ¶ 4 (2000) (“[A] claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.”). A claim’s status as dependent or independent depends on the substance of the claim in light of the language of § 112, ¶ 4, and not the form alone. See also Manual of Patent Examining Procedure (MPEP) § 608.01(m), (n) (August 2006); 37 C.F.R. § 1.75 (2007) (setting forth prop-er drafts for independent and dependent claims).

Claim 4 expressly recites the process of claim 1 and specifically requires a fertile transgenic plant obtained by the of the steps in claim 1. Further, it includes the additional step of obtaining progeny. Claim 4 thus incorporates the format specified by the statute for claims. Contrary to Monsanto’s claim 4 clearly references another claim, not simply a starting material. The claim might have used express language to clarify that it only invoked the product of the process in claim 1 as a starting but did not do so. Instead, the claim language reads claim 1 into claim 4.

At oral argument on appeal, Monsanto argued that claim 4 is a process claim that merely recites a product made by an process claim. Specifically, Monsanto stated that claim 4 is claiming a process using the starting material of a product which has been made by the process of steps 1, 2 and 3 of claim 1. This court finds this argument irrelevant to the resolution of the issue. Even if claim 4 is a product by process claim, Syngenta would still have to perform the steps of the process of claim 1 to infringe the product by process claim, i.e., claim 4 would only have according to the incorporation of the limitations of claim 1. Claim 4 would contain the process steps of claim 1, which by its language requires this court to read the limitation of claim 1 into the new claim.

Although in a somewhat unusual format, claim 4 is dependent from claim 1 because it only stands if all three steps recited in claim 1 have been performed. In other words, the additional fourth step of obtaining progeny depends on the performance of the process comprising the three steps recited in claim 1 for obtaining a fertile transgenic plant. Claim 4 contains each element of a dependent claim.

Further, the prosecution history of the '880 patent provides additional insight into the scope of claim 4. Originally-filed claim 30, which corresponds to patent claim 4, was incontestably a dependent claim. Original claim 30 recited:

30. The process of claim 23 further comprising (iv) obtaining progeny from said fertile transgenic plant of step (iii), which comprise said DNA.

(emphasis added). This language even more expressly required performance of all three steps of the process of claim 23 (which corresponded to issued claim 1).

Upon later amending original claim 30 after the prosecution closed, Monsanto carefully explained that its amendments “do not introduce new matter and are allowable without further search and consideration.” Moreover, the examiner accepted the amendment indicating the amendment was “directed to matters of form not affecting the scope of the invention.” These two statements underscore that Monsanto did not change a four-step claim (original claim 30) into a single-step claim (claim 4) with its amendment. Instead, claim 4, like its predecessor claim, as attested by the prosecution history, is in dependent form and incorporates the limits of the overarching independent claim.

The district court correctly interpreted and applied 35 U.S.C. § 112, ¶4 to read claims 4-9 of the '880 patent and claims 5-6 of the '863 patent as dependent. Therefore, this court affirms the district court’s claim construction.

B. Infringement

Turning to Monsanto’s appeal of the district court’s summary judgment ruling of non-infringement, Monsanto argues Syn-genta infringed the asserted patents under 35 U.S.C. § 271(a) or in the alternative under § 271(g). The district court held that because Syngenta did not infringe the methods of the independent claims, it could not infringe the methods of the asserted dependent claims.

According to § 112, ¶ 4, claims in dependent form include all the limitations of the claim incorporated by reference into the dependent claim. On appeal, Monsanto concedes that Syngenta has not infringed independent claim 1 of either Lundquist patent. Nevertheless, Monsanto insists that Syngenta infringed claims 4-9 of the '880 patent and claims 5-6 of the '863 patent. To reach this conclusion, Monsanto contends that, even if the asserted claims of the Lundquist patents are dependent claims, Syngenta should still be liable for infringing them, because each limitation of the independent claims of the Lundquist patents have been performed (albeit by Monsanto’s own subsidiary De-kalb). Alternatively, Monsanto contends that, even if the asserted claims of the Lundquist patents are dependent claims, Syngenta should still be liable for infringing them, because Syngenta infringes any “four-step” claimed process by completing the last step of “obtaining progeny” during the patent term (albeit with the first three steps occurring before the patents issued).

Monsanto’s first argument cannot prevail in light of this court’s decision in Wahpeton Canvas Co., Inc. v. Frontier, Inc., 870 F.2d 1546, 1552 (Fed.Cir.1989). In Wahpeton, this court explained:

One may infringe an independent claim and not infringe a claim dependent on that claim. The reverse is not true. One who does not infringe an independent claim cannot infringe a claim dependent on (and thus containing all the limitations of) that claim.

Id.

According to Monsanto, the district court misconstrued Wahpeton as holding that dependent claims cannot be “infringed” unless someone would be liable for infringing the independent claims from which they depend. Monsanto urges that Wahpeton only applies when the accused product or process lacks a limitation present in the independent claim, but not when all the independent limitations are missing. The Wahpeton rule typically applies in cases where the accused product or process lacks a single limitation from the independent claim. See Jeneric/Pentron, Inc. v. Dillon Co., Inc., 205 F.3d 1377, 1382-83 (Fed.Cir.2000). The rule does not change, however, where all of the steps of the independent claim are missing. In the present case, no one performed the three-step process of the independent claim “during the patent term,” as required by § 271(a). Indeed, Monsanto itself (through Dekalb) practiced the three-step process before the '863 and '880 patents issued.

Monsanto’s second argument is also inconsistent with the basic rule for infringement. As this court has stated many times, “[flor infringement of a process invention, all of the steps of the process must be performed, either as claimed or by an equivalent step.” EMI Group N. Am., Inc. v. Intel Corp., 157 F.3d 887, 896 (Fed.Cir.1998). As a result of this rule, the performance of the three steps (of independent claim 1) is a prerequisite for the infringement of the four-step process claims of the Lundquist patents. Furthermore, infringement under § 271(a) re quires use “without authority ... during the patent term.”

This ease lacks any basis for infringement under claim 1 because those steps occurred before patent issuance. Monsanto itself performed those three steps before issuance of the Lundquist patents. Thus, Monsanto itself authorized the first three steps of the claimed four-step process. Thus, this court finds no error in the district court ruling as to the claim of infringement under § 271(a). Further, this court reaches the same result with respect to Monsanto’s claim of infringement under § 271(g). Infringement is not possible under § 271(g) when the three first steps of the claimed process are performed before the issuance of the patent. In Mycogen Plant Science, Inc. v. Monsanto Co., this court held that § 271(g) “requires that the patent be issued and in force at the time that the process is practiced and the product is made.” 252 F.3d 1306, 1318 (Fed.Cir.2001) (finding no § 271(g) infringement where all process steps were practiced and product was made before patent issued), vacated on other grounds, 535 U.S. 1109, 122 S.Ct. 2324, 153 L.Ed.2d 153 (2002). This court explained “[bjecause domestic entities do not infringe a process patent if they practice the process before the beginning of the patent term, even if they sell the products of the process during the term of the patent, parallel treatment of overseas entities indicates that the statute does not reach pre-issuance use of the later-patented process.” Id. (citation omitted). Further, in Joy Technologies, Inc. v. Flakt, Inc., this court explained that a method or process claim is directly infringed only when the process is performed. 6 F.3d 770, 774 (Fed.Cir.1993). Thus, infringement of a multi-step method claim cannot lie by the performance of a single step after issuance of the patent when the initial steps were performed prior to issuance. Therefore, this court affirms the district court’s judgment that Syngenta’s products do not infringe claims 4-9 of the '880 patent and claims 5-6 of the '863 patent. Syngenta cannot be liable under § 271(a) or (g).

C. Enablement

The first paragraph of Section 112 of the Patent Act requires that a patent application include “a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” 35 U.S.C. § 112, ¶1. “[T]o be enabling, the specification of the patent must teach those skilled in the art how to make and use the full scope of the claimed invention without ‘undue experimentation.’ ” In re Wright, 999 F.2d 1557, 1561 (Fed.Cir.1993) (citing In re Vaeck, 947 F.2d 488, 495 (Fed.Cir.1991)); In re Wands, 858 F.2d 731, 736-37 (Fed.Cir.1988); In re Fisher, 57 C.C.P.A. 1099, 427 F.2d 833, 839 (1970).

The district court held claims 1, 5 and 6 of the '835 patent invalid under § 112 because the specification does not enable the full scope of the broad functional language in claim 1 without undue experimentation.

Claim 1 of the '835 recites:

A chimeric plant gene which comprises:

(a) a promoter sequence which functions in plant cells;

(b) a coding sequence which causes the production of RNA, encoding a chloroplast transit peptide/5-enolpyruvylshiki- mate-3-phosphate synthase fusion polypeptide, which chloroplast transit peptide permits the fusion polypeptide to be imported into a chloroplast of a plant cell; and

(c) a 3’ non-translated region which encoded a polyadenylation signal which functions in plant cells to cause the addition of polyadenylate nucleotides to the 3’ end of the RNA;

the promoter being heterologous with respect to the coding sequence and adapted to cause sufficient expression of the fusion polypeptide to enhance the glyphosate resistance of a plant cell transformed with the gene.

(emphases added). As this court noted in Plant Genetic Systems, “[f]lowering plants can be broadly categorized as monocotyledons (‘monocots’) and dicotyledons (‘dicots’), depending on whether the initial development of the seed produces one leaf (monocot) or two leaves (dicot).” 315 F.3d 1335, 1338 (Fed.Cir.2003).

The district court correctly construed claim 1 of the '835 patent to require the claimed gene to function in any plant cell, including both dicots and monocots. Indeed, the functional language of claim 1 is analogous to the functional language in In re Vaeck, 947 F.2d 488, 490 (Fed.Cir.1991). In Vaeck, this court held the limitation “[a] chimeric gene capable of being expressed in Cyanobacteria cells” required the claimed gene to function in all cyanobacte-ria. Id. at 495. This court affirmed the rejection of the Patent Office because there was “no reasonable correlation between the narrow disclosure in appellants’ specification and the broad scope of protection sought in the claims encompassing gene expression in any and all cyanobacte-ria.” Id. Indeed, cyanobacteria comprised approximately 150 different genera and was poorly studied and highly unpredictable. Id. at 493. Under these conditions, this court held full enablement would require undue experimentation. Id. at 496.

Just as the chimeric genes claimed in Vaeck were not limited to expression in a subset of cyanobacteria, claim 1 of the '835 patent extends to cells of all flowering plants, both monocots and dicots, and indeed to all plant cells. Once again, the '835 patent was filed before transformation of monocot cells was possible. Therefore, those skilled in the art could not transform a monocot plant cell as of the filing date of the patent application. The claim requires transformation of the plant cell. Without the ability to transform a monocot cell, one skilled in the art could not determine whether the plant gene could carry out the claimed functions and thus fall within the scope of the claim.

To counter this logic, Monsanto argues that the disputed claim language merely describes the operation of the discrete gene components in a plant cell, but does not operate as a limitation. In other words, Monsanto argues that the term “plant cell” should not convert chimeric gene claims into claims directed to plants or plant cells transformed with the claimed gene, particularly where the patent already contains separate claims directed to such plants and plant cells.

This court agrees with the district court. Monsanto’s patent recites broad functional language in its claims. This court in In re Goodman addressed a very similar issue, holding the full scope of Goodman’s patent not enabled due to an absence of reliable evidence of “gene transformation method of use with mono-cot plants” as of Goodman’s 1985 filing date. 11 F.3d 1046, 1052 (Fed.Cir.1993). Again, in Plant Genetic Systems, this court held practicing stable gene transformation for monocot cells in 1987 required undue experimentation. 315 F.3d at 1338. As in these prior cases, the evidence here does not demonstrate that as of the filing date of the '835 patent (July 7, 1986) the invention was enabled.

IV

As a final matter, Monsanto notes that for the purposes of the present appeal, the district court did not construe every disputed claim term. Rather, the district court only construed terms relevant to the present appeal. In a footnote, the district court stated “[f]or purposes of appeal, and consistent with the above conclusions of law, the court adopts the claim construction proposed by defendants (D.I.309) in connection with the asserted claims of the '880 and '863 patents ... [and] of the '835 patent.” Monsanto invites this court to vacate the district court’s claim constructions in the footnote. As none of the terms covered by the footnote are on appeal, this court does not need to reach this issue in its present decision.

The district court granted summary judgment that Syngenta did not infringe the asserted claims of U.S. Patents Nos. 5,538,880 and 6,013,863 and that claims 1, 5 and 6 of U.S. Patent No. 4,940,835 are invalid for lack of enablement. Because there are no genuine issues of material fact, and the district court’s judgment was adequately supported as a matter of law, this court affirms.

AFFIRMED

COSTS

Each party shall bear its own costs.

1 . The complaint was later amended by De-kalb Genetics Corporation to add Garst Seeds Company; Golden Harvest Seeds, Inc.; Garwood Seed Co.; Golden Seed Co., LLC; Sokmer Bros. Seed Company; Thorp Seed Co. and JC Robinson Seeds, Inc. as defendants.

2 . On July 28, 2004, one day after being sued by Dekalb, Syngenta Seed, Inc. filed a suit against Monsanto Company and Monsanto Technology LLC in the Delaware district court alleging antitrust violations. This suit was consolidated with the '835 patent case before the Delaware district court.